Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

BET inhibition synergizes with RLR signaling to enhance tumor immunogenicity and T cell recognition.

Cancer immunology research·2026

Same author

Hydrogel degradation products as immunomodulatory cues in neural injury: mechanisms and implications for neural repair.

Journal of materials chemistry. B·2026

Same author

Restoring STING expression in soft tissue sarcoma increases activation and function of tumor-infiltrating lymphocytes.

Cancer immunology, immunotherapy : CII·2026

Same author

From fork to fatherhood: Unveiling the link between dietary pattern indices and biochemical parameters of semen.

PloS one·2026

Same author

Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8<sup><b>+</b></sup> T cells.

Oncoimmunology·2026

Same author

Neutral sphingomyelinases restrict natural killer cells activity against lung cancer.

Cancer immunology, immunotherapy : CII·2026

Search research articles

Related Experiment Video

Updated: Dec 18, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Genetically modified immune cells targeting tumor antigens.

Mansour Poorebrahim¹, Mohammad Foad Abazari², Solmaz Sadeghi³

¹Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Pharmacology & Therapeutics

|June 20, 2020

Summary

Genetically modified immune cell therapies show promise for durable cancer treatment by targeting tumor antigens. Ongoing research focuses on identifying new antigens and improving cell generation for enhanced clinical efficacy.

Keywords:

Genetically modified immune cell Tumor antigen ‘Living’ therapy

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Dec 18, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Genetically modified immune cells offer a promising 'living' therapy for cancer.
These therapies have demonstrated durable responses in clinical studies.
Identifying tumor antigens and optimizing immune cell generation are key research areas.

Purpose of the Study:

To review the latest advancements in tumor antigen discovery.
To discuss progress in generating genetically modified immune cells.
To evaluate the clinical efficacy of these immunotherapies.

Main Methods:

Literature review of recent studies on tumor antigens.
Analysis of biotechnological developments in immune cell engineering.
Assessment of clinical trial data for immunotherapy efficacy.

Main Results:

Significant progress has been made in identifying tumor antigens.
Technical advancements are improving the generation and expansion of modified immune cells.
Immunotherapies show potential as both monotherapy and combination therapy.

Conclusions:

Genetically modified immune cells represent a powerful platform for cancer treatment.
Continued research into tumor antigens and cell engineering is crucial.
Optimizing these therapies can lead to improved patient outcomes.